Pfizer Inc. Announces Detailed Results Of OPT Compare Phase 3 Study Of Tofacitinib 5 Mg And 10 Mg Twice Daily Compared To High-Dose ENBREL® In Adults With Moderate-To-Severe Chronic Plaque Psoriasis

Published: Mar 24, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today detailed results from OPT Compare (A3921080), a Phase 3 study of tofacitinib, the first in a new class of treatment, oral Janus kinase (JAK) inhibitors, the safety and efficacy of which are being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Top-line results from OPT Compare were previously announced in October 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news